Nyrada Inc
NYR
Company Profile
Business description
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Contact
828 Pacific Highway
Suite 2, Level 3
GordonNSW2072
AUST: +61 294983390
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,421.70 | 21.90 | 0.26% |
| CAC 40 | 7,682.25 | 55.41 | 0.73% |
| DAX 40 | 23,317.03 | 201.07 | 0.87% |
| Dow JONES (US) | 41,300.06 | 186.09 | 0.45% |
| FTSE 100 | 8,531.97 | 27.36 | -0.32% |
| HKSE | 22,775.92 | 84.04 | 0.37% |
| NASDAQ | 17,845.60 | 107.44 | 0.61% |
| Nikkei 225 | 36,928.63 | 148.97 | 0.41% |
| NZX 50 Index | 12,467.03 | 29.86 | -0.24% |
| S&P 500 | 5,654.66 | 23.38 | 0.42% |
| S&P/ASX 200 | 8,191.70 | 13.40 | 0.16% |
| SSE Composite Index | 3,352.00 | 9.33 | 0.28% |